Zubair Malik is a Gastroenterology physician affiliated with Temple University. OpenAlex indexes 180 publications with 1,712 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3401 N Broad St
Philadelphia, PA 191405103
Telephone
215-707-9900Provider last certified this registry record 7 Oct 2024.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Phathom Pharmaceuticals, Inc.Program year202517 payments
- Merck Sharp & Dohme LLCProgram year20252 payments
- Ardelyx, Inc.Program year202517 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
77.9%Integrin Receptor Antagonist77.9%Vedolizumab100%Part B, office-administered≥11 patientsMetabolism & gastrointestinal
16.9%Proton pump inhibitor8%Omeprazole69%Pantoprazole Sodium26%Esomeprazole Magnesium4%Part D<11 patientsSerotonin-3 Receptor Antagonist2.7%Ondansetron Hcl89%Ondansetron Odt11%Part D<11 patients+ 8 more classes in this area
Nervous system
4.3%Other antidepressants3%Mirtazapine100%Part D≥66 patientsAzaspirodecanedione derivatives0.6%Buspirone Hcl100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( <scp>BESST</scp> )
Alimentary Pharmacology & Therapeutics
2023 - <scp>Gastrointestinal‐Specific</scp> symptom anxiety in patients with gastroparesis: Relationships to symptom severity and quality of life
Neurogastroenterology & Motility
2023 - Characteristics and outcomes of patients with gastroparesis using enteral and/or exclusive parenteral nutrition
Journal of Parenteral and Enteral Nutrition
2023 - Relationships among intragastric meal distribution during gastric emptying scintigraphy, water consumption during water load satiety testing, and symptoms of gastroparesis
American Journal of Physiology-Gastrointestinal and Liver Physiology
2023 - Postprandial symptoms in patients with symptoms of gastroparesis: roles of gastric emptying and accommodation
American Journal of Physiology-Gastrointestinal and Liver Physiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Criner, MD
Temple University
Yoshiya Toyoda, MD, PhD
Temple University
Lyle Ostrow, MD, PhD
Temple University
Michel Pontari, MD
Temple University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”